Use of gadolinium-based contrast agents in head and neck cancer diagnosis, staging, and monitoring: current applications and future perspectives - Takeaways - MDSpire

Use of gadolinium-based contrast agents in head and neck cancer diagnosis, staging, and monitoring: current applications and future perspectives

  • By

  • Marco Parillo

  • Federica Vaccarino

  • Andrea Falzone

  • Elena Salvador

  • Fabio M. Doniselli

  • Carlo C. Quattrocchi

  • Àlex Rovira

  • December 13, 2025

  • 0 min

Share

  • 1

    Head and neck cancers (HNCs) primarily originate from epithelial cells, with squamous cell carcinoma being the most common type.

  • 2

    MRI, enhanced with gadolinium-based contrast agents (GBCAs), is essential for accurate staging and monitoring of HNCs.

  • 3

    Concerns regarding GBCAs include nephrogenic systemic fibrosis and gadolinium retention in tissues, prompting regulatory guidelines for their use.

  • 4

    Advanced imaging techniques, such as 3D post-contrast T1-weighted MRI and perfusion-weighted imaging, enhance tumor assessment in HNCs.

  • 5

    Future developments in hybrid imaging, novel contrast agents, and AI tools are anticipated to improve HNC diagnosis and management.

Original Source(s)

Use of gadolinium-based contrast agents in head and neck cancer diagnosis, staging, and monitoring: current applications and future perspectives

  • by Marco Parillo, Federica Vaccarino, Andrea Falzone, Elena Salvador, Fabio M. Doniselli, Carlo C. Quattrocchi, Àlex Rovira

  • December 13, 2025

Related Content

Trauma CT and Unexpected Findings

Investigators evaluate classification of incidental findings on trauma whole-body CT.

AAE Revises Dental Trauma Guidance

Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models